Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma

Stopped Frequent adverse events occurred early in treatment with poor tolerability.

Conditions

• Scleroderma

Interventions

• DRUG: Imatinib mesylate
• OTHER: Placebo

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Collaborators

• [object Object]